XON - Intrexon Corporation

NYSE - NYSE Delayed Price. Currency in USD
13.25
-0.37 (-2.72%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close13.62
Open13.55
Bid12.61 x 100
Ask13.08 x 100
Day's Range13.18 - 13.65
52 Week Range10.26 - 26.99
Volume752,712
Avg. Volume1,766,106
Market Cap1.69B
Beta2.38
PE Ratio (TTM)N/A
EPS (TTM)-1.12
Earnings DateFeb 27, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.33
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1

    BOSTON, Feb. 13, 2018-- Ziopharm Oncology, Inc., today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate ...

  • GlobeNewswire7 days ago

    Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond

    BOSTON, Feb. 12, 2018-- Ziopharm Oncology, Inc., a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, ...

  • American City Business Journals13 days ago

    See the D.C.-area stocks hit hardest in the last week

    Several D.C.-area publicly traded companies saw their stock prices hit in recent days as U.S. stock exchanges saw a widespread selloff Friday, continuing into Monday trading. In the worst stock market ...

  • GlobeNewswire13 days ago

    Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance

    BOSTON, Feb. 06, 2018-- Ziopharm Oncology, Inc. today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company ...

  • ACCESSWIRE18 days ago

    Today’s Research Reports on Trending Tickers: Incyte Corporation and Intrexon Corporation

    NEW YORK, NY / ACCESSWIRE / February 1, 2018 / U.S. markets rallied late Wednesday to close in the green, with the Dow Jones and S&P 500 posting their best monthly gain since March 2016. The Dow Jones ...

  • GlobeNewswire20 days ago

    Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

    EXTON, Pa., Jan. 30, 2018-- Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue, today announced that it obtained ...

  • GuruFocus.com21 days ago

    First Eagle Fund of America 4th Quarter Commentary

    Review of holdings and markets

  • GuruFocus.com21 days ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week from the following companies: Intrexon, OPKO and Chemical Financial

  • Better Buy: Intrexon Corporation vs. Celgene
    Motley Fool22 days ago

    Better Buy: Intrexon Corporation vs. Celgene

    It's not a difficult decision.

  • Why IBM, GNC Holdings, and Intrexon Slumped Today
    Motley Foollast month

    Why IBM, GNC Holdings, and Intrexon Slumped Today

    Find out more about how earnings results held back Big Blue.

  • PR Newswirelast month

    Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters

    GERMANTOWN, Md., Jan. 19, 2018 /PRNewswire/ -- Intrexon Corporation (XON) announced today the closing of its previously announced underwritten public offering of common stock. Intrexon sold 6,900,000 shares of its common stock at a public offering price of $12.50 per share, including the exercise in full by the underwriters of their option to purchase an additional 900,000 shares of common stock.  Gross proceeds to Intrexon from the offering are expected to be approximately $86 million before deducting the underwriting discount and other offering expenses payable by Intrexon. JMP Securities LLC acted as sole book-running manager and Stifel acted as lead manager for the offering.

  • PR Newswirelast month

    Intrexon Prices Public Offering of Common Stock

    GERMANTOWN, Md., Jan. 17, 2018 /PRNewswire/ -- Intrexon Corporation (XON) announced today that it has priced its previously announced underwritten public offering of common stock consisting of 6,000,000 shares at a public offering price of $12.50 per share. The offering is expected to close on January 19, 2018, subject to customary closing conditions. Gross proceeds to Intrexon from the offering are expected to be approximately $75 million before deducting the underwriting discount and other offering expenses payable by Intrexon and excluding any exercise of the underwriters' option.

  • PR Newswirelast month

    Intrexon Announces Proposed Public Offering of Common Stock

    GERMANTOWN, Md., Jan. 16, 2018 /PRNewswire/ -- Intrexon Corporation (XON) announced today it has commenced an underwritten public offering of shares of its common stock. In addition, Intrexon intends to grant the underwriters a 30-day option to purchase additional shares of its common stock.  The offering is subject to market and other conditions and there can be no assurances as to whether or when the offering may be completed, or as to the size or terms of the offering. JMP Securities LLC is acting as sole book-running manager for the offering.

  • GlobeNewswirelast month

    AquaBounty Technologies, Inc. Announces $12 Million Underwritten Public Offering

    MAYNARD, Mass., Jan. 12, 2018-- AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation, ...

  • See what the IHS Markit Score report has to say about Intrexon Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Intrexon Corp.

    Short interest is high for XON with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting XON. Over the last one-month, outflows of investor capital in ETFs holding XON totaled $958 million.

  • GlobeNewswirelast month

    Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference

    -Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO ®-- Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology ...

  • PR Newswire2 months ago

    Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8

    GHENT, Belgium, Jan. 4, 2018 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that Pieter Rottiers, PhD, ActoBio's Chief Executive Officer, will present at the Biotech Showcase 2018 Conference in San Francisco on Monday, January 8th at 2 p.m. Pacific Time.  The presentation will highlight the innovative, proprietary ActoBiotics® drug delivery platform for oral and topical administration of biologicals to address unmet medical needs for diverse health indications. "ActoBio Therapeutics combines world-class science, preclinical and clinical-stage products, and a leadership team with over 20 years hands-on experience developing the platform.  ActoBio has reached a significant level of development and is well prepared to move forward to create significant new therapeutic modalities across a broad set of markets with strong growth dynamics including oral, gastrointestinal, and autoimmune/allergic disorders.  Using the innovative ActoBiotics® platform, we have built a strong R&D pipeline with the latest stage therapeutic candidate in Phase 2b and an extensive portfolio of candidates both partnered and self-owned ready for clinical development across a number of conditions," Dr. Rottiers commented.

  • PR Newswire2 months ago

    Intrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference

    GERMANTOWN, Md. , Jan. 4, 2018 /PRNewswire/ --  Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...

  • Barrons.com2 months ago

    A Cash Infusion From the Boss Props Up Intrexon -- For Now

    Shares of Intrexon (XON) have popped 19% this week, to 14 bucks, after the gene-tinkering outfit said its chief executive had bought some $14 million worth of its stock from the company. Intrexon’s most recent balance sheet showed only a few quarters’ worth of cash left in the till at recent burn rates. After years of saying it was on the cusp of greatness with its “synthetic biology,” Intrexon might find it is out of money, barring additional cash infusions.

  • PR Newswire2 months ago

    Intrexon Corporation Annual CEO Letter

    GERMANTOWN, Md., Jan. 2, 2018 /PRNewswire/ -- Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, sent the following annual letter to his colleagues at Intrexon.

  • Capital Cube2 months ago

    ETFs with exposure to Intrexon Corp. : December 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Intrexon Corp. Here are 5 ETFs with the largest exposure to XON-US. Comparing the performance and risk of Intrexon Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswire2 months ago

    ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference

    BOSTON, Dec. 21, 2017-- ZIOPHARM Oncology, Inc., today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco ...

  • Capital Cube2 months ago

    ETFs with exposure to Intrexon Corp. : December 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Intrexon Corp. Here are 5 ETFs with the largest exposure to XON-US. Comparing the performance and risk of Intrexon Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Why Intrexon (XON) Could Be Positioned for a Slump
    Zacks2 months ago

    Why Intrexon (XON) Could Be Positioned for a Slump

    Investors may consider dropping Intrexon (XON) stock that has seen both price depreciation as well as downward estimate revision in the past one month.